Tag Archives: Zeinab Hosseinidoust

Collaborative research agreement (CRA) with McMaster University (Canada) for development of catheter coating

Leave a reply

I don’t always do as good a job at covering the commercialization of emerging technologies as I’d like, so, this December 13, 2023 news item on Yahoo News was a welcome discovery,

Oakville, Ontario–(Newsfile Corp. – December 13, 2023) – FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX“), a nanotechnology company developing surface protection coatings is pleased to announce it has entered into a Collaborative Research Agreement (“CRA“) dated December 12, 2023 with McMaster University (“McMaster“) which details the research and development plan to create a protective catheter coating using our nanotechnology licensed pursuant to the license agreement dated February 5, 2021, as amended, between the Company and McMaster.

Dr. Carolyn Myers, President and CEO of FendX, stated, “We are excited about the prospect of developing a coating for catheters using our nanotechnology which we believe will reduce catheter blockage caused by either blood clots or bacterial biofilms. Early work conducted at McMaster has demonstrated significant reduction in the adherence of both bacteria and blood which could potentially translate to reduced bacterial biofilm or blood clot formation. [emphasis mine] Our aim is to further this research to tackle the medical need to reduce catheter blockage rates, which can be costly and interfere with patient therapy. We anticipate the development of this coating formulation will also strengthen our overall intellectual property portfolio.”

The CRA outlines more fully the research and development work to be conducted by McMaster on behalf of FendX as well as a payment schedule for the maximum research funding requirements. The term of the CRA is for 24 months commencing on the effective date of December 1, 2023, unless terminated in accordance with the provisions of the CRA. In the first and second year, maximum research funding to McMaster will be $150,547 each year.

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

…

For more information, please visit https://fendxtech.com/ and the Company’s profile on SEDAR+ at www.sedarplus.ca.

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the catheter coating development and anticipated benefits; the Company’s belief that the catheter coating could reduce catheter occlusions caused by either blood clots or bacterial biofilms; statements regarding strengthening the Company’s overall intellectual property portfolio; the Company’s belief that REPELWRAP™ will have applications in healthcare settings and other industries; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company’s public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company’s such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors should change.

FendX offers next to no information about their technology or the proposed work with McMaster as seen in this excerpt from the Our Technology webpage on the FendX website,

Our patent-pending licensed nanotechnology works by combining a hierarchical wrinkled molecular structure with chemical functionalization to create nano-surfaces with repelling properties that prevent adhesion of bacteria, viruses and liquids.

Inspired by the water-resistant surface of the lotus leaf

Our nanotechnology causes both high surface tension (e.g., water) and low surface tension (e.g., oil) liquids to form droplets when they come in contact with the nano-surface.

The repelling properties of our nano-surfaces prevents adhesion of bacteria and viruses.

We believe our technology will have numerous applications and opportunities in healthcare and other industries.

That’s it. No technical details and not a single research study is cited.

While McMaster University doesn’t seem to have issued any news releases about their joint research effort with FendX, there are two research papers that I’m reasonably confident are relevant. From the Didar Lab Publications webpage, here are links and citation for both papers,

An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces by Maryam Badv, Iqbal H. Jaffer, Jeffrey I. Weitz & Tohid F. Didar. Scientific Reports volume 7, Article number: 11639 (2017) DOI: https://doi.org/10.1038/s41598-017-12149-1 Published: 14 September 2017

This paper is open access.

Highly Stable Hierarchically Structured All-Polymeric Lubricant-Infused Films Prevent Thrombosis and Repel Multidrug-Resistant Pathogens by Elisabet Afonso, Fereshteh Bayat, Liane Ladouceur, Shadman Khan, Aránzazu Martínez-Gómez, Jeffrey I. Weitz, Zeinab Hosseinidoust, Pilar Tiemblo, Nuria García, and Tohid F. Didar. CS Appl. Mater. Interfaces 2022, 14, 48, 53535–53545 DOI: https://doi.org/10.1021/acsami.2c17309 Publication Date: November 22, 2022 Copyright © 2022 American Chemical Society

This paper is behind a paywall.

Maple syrup as an antibiotic helper?

Leave a reply

This maple syrup research is from McGill University in Montréal, Québec (from an April 16, 2015 McGill University news release; also on EurekAlert),

A concentrated extract of maple syrup makes disease-causing bacteria more susceptible to antibiotics, according to laboratory experiments by researchers at McGill University.

The findings, which will be published in the journal Applied and Environmental Microbiology, suggest that combining maple syrup extract with common antibiotics could increase the microbes’ susceptibility, leading to lower antibiotic usage. Overuse of antibiotics fuels the emergence of drug-resistant bacteria, which has become a major public-health concern worldwide.

Prof. Nathalie Tufenkji’s research team in McGill’s Department of Chemical Engineering prepared a concentrated extract of maple syrup that consists mainly of phenolic compounds. Maple syrup, made by concentrating the sap from North American maple trees, is a rich source of phenolic compounds.

The researchers tested the extract’s effect in the laboratory on infection-causing strains of certain bacteria, including E. coli and Proteus mirabilis (a common cause of urinary tract infection). By itself, the extract was mildly effective in combating bacteria. But the maple syrup extract was particularly effective when applied in combination with antibiotics. The extract also acted synergistically with antibiotics in destroying resistant communities of bacteria known as biofilms, which are common in difficult-to-treat infections, such as catheter-associated urinary tract infections.

“We would have to do in vivo tests, and eventually clinical trials, before we can say what the effect would be in humans,” Tufenkji says. “But the findings suggest a potentially simple and effective approach for reducing antibiotic usage. I could see maple syrup extract being incorporated eventually, for example, into the capsules of antibiotics.”

The scientists also found that the extract affects the gene expression of the bacteria, by repressing a number of genes linked with antibiotic resistance and virulence.

All maple syrup samples used in the study were purchased at local markets in Montreal, then frozen until the beginning of each experiment, which involved a series of steps to produce the phenolic-rich extract.

Tufenkji, who holds the Canada Research Chair in Biocolloids and Surfaces, has also studied the potential for cranberry derivatives to fight infection-causing bacteria. The new study is co-authored by postdoctoral fellows Vimal Maisuria and Zeinab Hosseinidoust.

Here’s a link to and a citation for the paper which at this time (April 24, 2014) is not yet published,,

Polyphenolic Extract from Maple Syrup Potentiates Antibiotic Susceptibility and Reduces Biofilm Formation of Pathogenic Bacteria by Vimal B. Maisuria, Zeinab Hosseinidoust, and Nathalie Tufenkji. doi: 10.1128/AEM.00239-15 AEM [Applied and Environmental Microbiology].00239-15

My guess is that this paper will be behind a paywall. Fear not! There is a very informative 3 mins. or so video,

I particularly appreciated the maple leaf-shaped glass container (still full) which is shown prominently when the researcher mentions purchasing the syrup from local markets.